Cell line · CVCL_1258
Papers93
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 93
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| VCP-Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cytotoxic Dihydroagarofuran Sesquiterpenoids Isolated From the Roots of Tripterygium wilfordii. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer. | Signal Transduct Target Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E modulates vulnerability to CDC7 kinase inhibition. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. | Antib Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LDAcoop: Integrating non-linear population dynamics into the analysis of clonogenic growth in vitro. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer. | NPJ Breast Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1258/papers